| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.8M | — | +97.9% |
| Cost of Revenue | $3.4M | — | +52.9% |
| Gross Profit | $1.4M | — | +586.9% |
| R&D Expense | $1.8M | — | -27.7% |
| SG&A Expense | $6.5M | — | -9.3% |
| Operating Income | -$7.4M | — | +21.8% |
| Net Income | -$28.1M | — | -49.5% |
| EPS (Basic) | -$0.61 | — | -771.4% |
| EPS (Diluted) | -$0.61 | — | -771.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.7M | -42.3% | -68.6% |
| Accounts Receivable | $2.0M | -1.4% | -30.4% |
| Inventory | $1.4M | +140.6% | +187.8% |
| Current Assets | $16.8M | -34.2% | -45.4% |
| Total Assets | $105.5M | -18.2% | +12.5% |
| Current Liabilities | $10.0M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.7M | — | +10.9% |
| Capital Expenditures | $174K | — | +44.4% |
| Investing Cash Flow | -$1.5M | — | +96.5% |
| Financing Cash Flow | $4.6M | — | -90.6% |
| Free Cash Flow | -$8.9M | — | +10.2% |
| +197.4% |
| Total Liabilities | $10.9M | +48.6% | +165.1% |
| Stockholders' Equity | $94.6M | -22.2% | +5.5% |